Is getting a $99 DNA test really hazardous to your health? Our editor-in-chief decodes an innovation dustup.
When we put 23andMe CEO Anne Wojcicki on the cover of Fast Company's November issue, we didn't expect the FDA to yank the company's $99 DNA test off the market a few weeks later. Yet there's a reason we called Wojcicki "the most daring CEO in America": Her company's product challenges established conventions about medical practices, research, insurance, and more. So is that challenge at the heart of the FDA's rebuke? Or did something more basic derail Wojcicki's mission?